Utilizing proteomics and phosphoproteomics to predict ex vivo drug sensitivity across genetically diverse AML patients
Sara J.C. Gosline, Cristina E. Tognon, Michael D. Nestor, Sunil Kumar Joshi, Rucha V. Modak, Alisa Damnernsawad, Jamie Moon, Joshua Hansen, Chelsea M. Hutchinson-Bunch, Marina A. Gritsenko, Karl Weitz, Elie A. Traer, Brian J Drucker, Anupriya Agarwal, Paul Piehowski, , Karin Rodland
The paper predicts ex vivo drug sensitivity in AML patients using proteomic and phosphoproteomic signatures, showing better accuracy than mutation or mRNA-based signatures.
bioRxiv · Jun 4, 2021 · PreprintBioinformatics